News

AddToAny

Google+ Facebook Twitter Twitter

CJD treatment trialled for first time

In a world first, doctors have been given permission to give a British man with CJD a pioneering treatment.

CJD is a rare but lethal brain disease for which there is no known cure, but the Court of Protection has given permission for the trial use on a human for the first time.

Scientists say lab testing of the man-made antibody has been encouraging, but they admit they do not know how their patient will respond.

The treatment is called PRN100 and aims to prevent abnormal prions from being able to attach themselves to healthy proteins, meaning that they cannot grow and cause devastation throughout the brain.

University College London Hospitals NHS Foundation Trust (UCLH) is set to use it in a patient for the first time after a judge confirmed that it was lawful.

Professor John Collinge, Director of the Medical Research Council Prion Unit at UCLH, who led the development of the treatment, said: “As this is the first time this treatment has been used in humans we cannot predict what the outcome will be, but laboratory testing has shown the potential to treat prion infection.”


Image credit | iStock

Related Articles

CRISPR-Cas9 gene editing complex, illustration.Image credit - Science-Photo-Library-f0248864

Activating genes using CRISPR technology

There are over 7000 different rare genetic diseases, and often it can be a significant challenge and take a long time to receive a correct diagnosis.

Blue helix human DNA structure-Image credit-shutterstock-1669326868

The search for genes that cause diseases

A new statistical tool developed by researchers at the University of Chicago improves the ability to find genetic variants that cause disease.

pathogenspreadhr-CREDIT-spooky-pooka

Figuring out the threats: Problem-solving with genomics

As the COVID-19 enquiry continues to unpick the tangled threads of the pandemic response, little has been said about one of the most effective weapons against the SARS-Cov-2 virus – pathogen genomics.

breast cancer cells - CREDIT - Science Photo Library-c0559159

Breast cancer cells’ self-sacrifice is potential cause of relapse

For patients with early-stage breast cancer, there is a 7% to 11% chance of relapse within five years after receiving initial treatment.

Top